Rationale: FK506-binding proteins FKBP12.6 and FKBP12 are associated with cardiac ryanodine receptors (RyR2), and cAMP-dependent protein kinase A (PKA)-dependent phosphorylation of RyR2 was proposed to interrupt FKBP12.6-RyR2 association and activate RyR2. However, the function of FKBP12.6/12 and role of PKA phosphorylation in cardiac myocytes are controversial. Objective: To directly measure in situ binding of FKBP12.6/12 to RyR2 in ventricular myocytes, with simultaneous Ca sparks measurements as a RyR2 functional index. Methods and Results: We used permeabilized rat and mouse ventricular myocytes, and fluorescently-labeled FKBP12.6/12. Both FKBP12.6 and FKBP12 concentrate at Z-lines, consistent with RyR2 and Ca spark initiation sites. However, only FKBP12.6 inhibits resting RyR2 activity. Assessment of fluorescent FKBP binding in myocyte revealed a high FKBP12.6-RyR2 affinity (K d ‫1.0؎7.0؍‬ nmol/L) and much lower FKBP12-RyR2 affinity (K d ‫07؎602؍‬ nmol/L). Fluorescence recovery after photobleach confirmed this K d difference and showed that it is mediated by k off . RyR2 phosphorylation by PKA did not alter binding kinetics or affinity of FKBP12.6/12 for RyR2. Using quantitative immunoblots, we determined endogenous [FKBP12] in intact myocytes is Ϸ1 mol/L (similar to [RyR]), whereas [FKBP12.6] is <150 nmol/L. Conclusions: Only 10% to 20% of endogenous myocyte RyR2s have FKBP12.6 associated, but virtually all myocyte FKBP12.6 is RyR2-bound (because of very high affinity). FKBP12.6 but not FKBP12 inhibits basal RyR2 activity. PKA-dependent RyR2 phosphorylation has no significant effect on binding of either FKBP12 or 12.6 to RyR2 in myocytes. (Circ Res. 2010;106:1743-1752.)
C ardiac ryanodine receptors (RyR2) are sarcoplasmic reticulum (SR) Ca release channels, crucial in excitation-contraction coupling. 1 Dysfunctional RyR2, exhibiting enhanced Ca leak has been implicated in arrhythmogenesis and heart failure (HF). 1 Homotetrameric RyR2s have a transmembrane channel domain, and regulatory and scaffolding cytoplasmic domain.
In heart, FK506 binding protein (FKBP) isoforms FKBP12 and FKBP12.6 are coexpressed and can bind RyR2 at a stoichiometry of 4 FKBP per RyR tetramer. 2, 3 FKBP12 binds RyR2 with much lower affinity, but is much higher in concentration in heart than FKBP12.6. 4 Nevertheless, FKBP12 and 12.6 share 85% sequence homology and similar 3D structures. 5 Human and rat FKBP12 differ in only 3 residues, and human and rat FKBP12.6 are identical. This makes study of human FKBP function in rat myocytes reasonable.
Effects of FKBPs on RyR2 activity in myocytes are controversial. Some groups reported that dissociation of FKBP12.6 from RyR2 by immunosuppressants (rapamycin or FK506) activated RyR2 channels and induced subconductance states. 6 -8 RyR2 point mutations associated with cardiac sudden death may also exhibit altered FKBP12.6 interaction, 9 and FK506 can alter resting Ca 2ϩ spark frequency (CaSpF) and SR Ca 2ϩ content. 7, 8, 10 FKBP12.6 overexpression also increased SR load and enhanced contraction. 11 However, others reported that FKBP12.6 removal had no effect on RyR2 activity, 3, 12 and failed to observe RyR2 subconductance states in channels from FKBP12.6 knockout mice. 13, 14 Some groups suggest that FKBP12 affects RyR2 differently from FKBP12.6. [15] [16] [17] 20 Therefore, FKBP12/12.6 binding and RyR2 effects remain unclear, especially in the cardiomyocyte environment (as studied here).
Altered FKBP-RyR2 interaction is a prominent hypothesis explaining increased SR Ca leak in HF via RyR2 hyperphos-phorylation and FKBP dissociation from RyR2. 19 However, Li et al found that cAMP-dependent protein kinase A (PKA)dependent RyR2 phosphorylation did not alter resting RyR2 function in mouse myocytes without phospholamban (PLB) and increased SR Ca load, 20 Xiao et al reported that PKA phosphorylation at RyR2-Ser2808 did not dissociate FKBP12.6, 21 and Jiang et al found that in HF there was neither FKBP12.6 dissociation from RyR2 by PKA hyperphosphorylation nor increased RyR2 channel activity. 22 Whether and how PKA phosphorylation of RyR2 affects FKBP-RyR2 interaction requires more study.
Here we characterize in the myocyte environment the interaction between FKBP12/12.6 and RyR2, its functional consequences, and modulation by PKA-dependent phosphorylation. Using fluorescent FKBP12/12.6 (F-FKBP), we simultaneously assessed physical association-dissociation of FKBP12/12.6 with RyR2, and RyR2 activity (via Ca sparks) in permeabilized ventricular myocytes. We found that: (1) both FKBP12.6 and FKBP12 bound to RyR2 (K d Ϸ1 nmol/L and 200 nmol/L, respectively); (2) FKBP12.6 but not FKBP12 inhibited CaSpF; (3) the binding properties of FKBP12.6/12-RyR2 were not changed by PKA-dependent phosphorylation of RyR2; and (4) endogenous FKBP12 was Ϸ1 mol/L cytosol and FKBP12.6 Ϸ100 nmol/L cytosol.
Methods
Rat and mouse ventricular myocytes were isolated and permeabilized as previously described (see the Online Data Supplement, available at http://circres.ahajournals.org). 23 F-FKBP12.6 and F-FKBP12 were characterized using circular dichroism spectroscopy and ligandbinding studies (Online Figure I ). 24 Consistent with previous reports, 25 F-FKBP constructs have the same secondary structure, RyR binding affinity and RyR1 effects as unlabeled and wild-type (WT) FKBPs.
Results

Localization of FKBP12.6/12 in Permeabilized Ventricular Myocytes
Saponin-permeabilized rat ventricular myocytes were incubated with F-FKBP12.6 or 12. Figure 1A shows a confocal myocyte image with 20 nmol/L F-FKBP12.6 (note that bath supply of F-FKBP12.6 is inexhaustible). The cross-striated sarcomeric pattern colocalizes with Di-8-ANEPPS (Online Figure III ), used to identify transverse tubules at the Z-line. Figure 1B shows that line scan fluorescence intensity peaks at Z-lines exhibit an interpeak distance (Ϸ2 m) that matches sarcomere length. The same striation pattern was seen for F-FKBP12 (Online Figure II) , but with lower contrast, because of lower RyR2 affinity (ie, bath F-FKBP12 fluorescence is higher when RyR2 saturates). Preincubation with WT-FKBP12.6 (100 nmol/L) completely prevented the appearance of striations, indicating that F-FKBP12.6/12 bind to the same sites as WT-FKBP12.6, and that there is little nonspecific binding. Ca sparks can be measured simultaneously using rhod-2, and superimposition of F-FKBP and spark images ( Figure 1C and 1D) shows that Ca spark initiation sites coincide with F-FKBP12.6 localization ( Figure  1E ). These data indicates that FKBP12.6/12 bind at the Z-line region where SR Ca release initiates during Ca sparks.
Effects of cAMP and Rapamycin on FKBP Binding and Resting SR Ca Release
Ca sparks are fundamental SR release events during rest and excitation-contraction coupling, 1 and are a readout of elementary RyR2 function in myocytes. We simultaneously measured Ca sparks and F-FKBP12.6/12 association and dissociation, providing direct online correlation between FKBP-RyR2 interaction and functional consequences. Figure 2A shows FKBP12 (1 mol/L) wash-in and Z-line binding (expressed as the difference between Z-line and M-line fluorescence). F-FKBP12 wash-in was rapid, reaching apparent steady state in 2 to 3 minutes. Rapamycin (20 mol/L) caused rapid F-FKBP12 wash-out (rapid decrease of Z-line fluorescence) despite a constant bath [F-FKBP12], but was similar in kinetics to simple wash-out of F-FKBP12. Neither F-FKBP12 nor rapamycin significantly altered CaSpF ( Figure 2B ), although rapamycin increased spark duration ( Figure 2F ). Small apparent decreases in spark amplitude and width were seen with both FKBP12 and rapamycin ( Figure 2D and 2E). These might reflect real FKBP12 actions on RyR2, but the fact that both addition (ϩFKBP12) and removal (ϩrapamycin) had identical effects, makes us think these (and any tendency of CaSpF change in Figure 2B ) are not simply attributable to FKBP12. Moreover, wash-out of bath F-FKBP12 caused dissociation of F-FKBP12 from the Z-line ( Figure 2A) 15, 16 ). Parallel studies using nonfluorescent WT FKBP12 also showed no effect on CaSpF (109Ϯ7% of control; rapamycin 105Ϯ8% of control), and both FKBP12 and rapamycin caused similar slight decreases in Ca spark amplitude and width (12 and 6% respectively; PϽ0.05), whereas spark duration was unaltered (96% to 97% of control). Activation of PKA by cAMP to phosphorylate RyR2 (as in 20 ) did not change FKBP12 binding (Figure 2A ), but increased CaSpF by Ͼ50%. We previously showed that this CaSpF enhancement was entirely attributed to PLB phos-phorylation and consequently increased SR Ca load. 20 Therefore, these data suggest that cAMP-dependent PKA phosphorylation does not alter FKBP12 binding to RyR2. Note that bath F-FKBP is an inexhaustible pool, and that RyR2 saturation in intact cells may differ. Figure 3A shows F-FKBP12.6 (100 nmol/L) wash-in, and Z-line binding also rapidly reached steady state (Ϸ2 minutes). F-FKBP12.6 binding to RyR2 was paralleled by a small, but highly significant decrease in CaSpF (18%) and a logically consequent increase in SR Ca load (of similar percent, Figure  3B ). Spark amplitude and duration were also decreased ( Figure 3D and 3F). These data agree with reports that FKBP12.6 inhibits resting RyR2, thus enhancing SR Ca content. 11 Using WT-FKBP12.6 (unlabeled), we found similar results (24Ϯ5% decrease in CaSpF, 15Ϯ1% decrease in spark amplitude; unaltered width and duration). Addition of cAMP/okadaic acid (OA) did not significantly alter F-FKBP12.6 binding ( Figure 3A ), but increased both CaSpF and SR Ca load ( Figure 3B ). Because F-FKBP12.6 binding was unaltered by cAMP, its dissociation cannot explain the enhanced CaSpF. Moreover, a primary enhancement of SR Ca leak should reduce SR Ca load (opposite to observed). We conclude that PKA-dependent phosphorylation does not alter RyR2 binding of FKBP12.6, but enhances CaSpF secondary to PLB phosphorylation-dependent increase in SR Ca content. 20 Unlike F-FKBP12, wash-out of F-FKBP12.6 was extremely slow on removal of bath F-FKBP12.6, suggesting much higher affinity for F-FKBP12.6 (see below). Even rapamycin addition after F-FKBP12.6 equilibration only very slowly decreased fluorescence, without significant CaSpF alteration within 10 minutes. Thus, FKBP12.6 (but not FKBP12) inhibited resting RyR2 in situ, but cAMPdependent PKA phosphorylation had no acute effect on FKBP12.6/12-RyR2 binding.
FKBP12.6/12 Binding Kinetics
Three methods were used to measure FKBP-RyR2 binding affinity and kinetics.
Steady-State K d and B max Measurement
To measure FKBP12.6 binding affinity in situ, we incubated permeabilized myocytes with different [F-FKBP12.6]. Figure  4A and 4B shows that F-FKBP12.6 binding is prevented by 20 mol/L rapamycin. This also shows that F-FKBP12.6 fluorescence inside myocytes was almost the same as in the bath (providing quantitative control for analysis). Fluorescence intensity at Z-line, M-line, and cell average were plotted versus bath [F-FKBP12.6] ( Figure 4D ). The average fluorescence intensity represents the overall bound F-FKBP12.6 in myocytes. FKBP12.6 binding exhibited an apparent dissociation constant (K d ) in ventricular myocytes of Ϸ1 nmol/L at 100 nmol/L [Ca], higher affinity than a previous report, 3 Figure 4E ). The apparent B max (Ϸ1 mol/L) is close to our previous measurements of total concentration of RyR2 monomers in rat ventricular myocytes, based on [ 3 H]-ryanodine binding. 26 Therefore, our data agree with RyR2 being the main highaffinity binding site for FKBP12.6, and with a stoichiometry of 4 FKBP12.6 per RyR2 tetramer. Note that additional soluble FKBP binding targets might be lost by myocyte permeabilization. Pretreatment with cAMP/OA did not affect steady-state affinity or B max for FKBP12.6 ( Figure 4E ). Similar B max and cAMP results were obtained for steady-state binding of F-FKBP12, except FKBP12 had a much lower affinity (K d Ϸ200 nmol/L, Figure 4F ). Thus, rapamycin prevented FKBP12.6/12 binding to RyR2, but cAMP-dependent PKA phosphorylation had no effect on either apparent K d or B max of FKBP12.6/12-RyR2 binding.
Binding Kinetics of FKBP12.6/12 Measured by Fluorescence Recovery After Photobleaching
Even if cAMP doesn't affect K d of FKBP12.6/12-RyR2, it might change association and dissociation rate constants (k on and k off , respectively). We used fluorescence recovery after photobleaching (FRAP) to investigate binding kinetics of FKBP12.6/12. 27 Figure 5A shows a myocyte equilibrated with 1 nmol/L F-FKBP12.6, immediately after photobleaching 3 regions of interest (ROIs), and where striations have partially recovered at 30 minutes (right). This FRAP indicates replacement of photobleached F-FKBP12.6 with fresh F-FKBP12.6 from the bath, and depends on k on and k off . 28 Figure 5B shows exponential fits of FRAP with first order rate constant, k FRAP . This provides an integrated measurement of k on and k off (k FRAP ϭk on [FKBP12.6]ϩk off ) and measurement at different [F-FKBP12.6] allows determination of k on , k off , and K d (Figure 5C ). 28 The apparent K d ϭ1.3 nmol/L for FKBP12.6-RyR2 agrees with our steady-state K d measurements. Rapamycin (20 mol/L) completely prevented FRAP ( Figure 5C ). Inclusion of cAMP/OA caused no significant change in either k on or k off , suggesting that cAMP-dependent PKA phosphorylation does not affect the binding kinetics of FKBP12.6 to RyR2 (see also Figure 6 , C and E).
Diffusion of F-FKBP12.6 is Ͼ1000 times faster than FRAP and is thus not rate limiting (eg, extracellular FRAP in ROI3 was Ͻ2 s versus Ϸ1000 s in the cell; Figure 5B ). FRAP kinetics were also the same at the cell center or edge (ROI1 versus -2), suggesting that intracellular F-FKBP12.6 diffusion is not rate-limiting in our FRAP measurement (see also below).
FKBP12 has a much lower affinity for RyR2, which accelerates FRAP compared to FKBP12.6. This has two practical consequences. First, FKBP12 FRAP must be measured on a faster time scale, using line-scan mode. 27 Second, F-FKBP12 diffusion may contribute to the measured FRAP, so it must be assessed. For line FRAP, we bleach a single line and monitor FRAP in that line at much lower laser power. As diffusion controls, we measured FRAP of F-dextran (molecular mass, 10 000 Da) in the myocyte (Online Figure IV) , which recovered with a single time constant (Ϸ1.7 secϭ1/ k FRAP ), and F-FKBP12 where binding was blocked by nonfluorescent FKBP12.6 (or rapamycin), giving Ϸ1 sec. FRAP of FKBP12 (without blocking binding) was always best fit with a double exponential with a fast component (Ϸ1 sec; taken as diffusion), and a slower component (ϭ6 to 10 sec) attributed to RyR2 binding. The slower k FRAP component was plotted as a function of [F-FKBP12] to extract k on , k off , and K d ( Figure 5D ). The k on for FKBP12 was similar to that of FKBP12.6, whereas k off was 150 times faster than FKBP12.6, and consequently K d (210 nmol/L) was Ϸ150 times higher than for FKBP12.6 and agrees with the steady-state K d measurements. Similar experiments were done in the presence of cAMP/OA, which again had no effect on k on , k off , or K d of FKBP12-RyR2 binding (see also Figure 6 , D and E).
We previously showed that this cAMP/OA treatment in permeabilized ventricular myocytes leads to maximal RyR2 phosphorylation ( 32 P incorporation) within 5 minutes. 20 To test whether RyR2 phosphorylation increased here, we assessed RyR2 phosphorylation level at Ser2809 by quantitative western blot. Figure 7C shows results using isolated myocytes treated as in the confocal studies. Basal phosphorylation at Ser2809 is substantial (as in our previous reports 20, 29 ). Permeabilization (before cAMP/OA exposure) produced a trend toward increase, but cAMP/OA treatment approximately doubled phosphorylation to what may be maximal phosphorylation. Figure 6A shows the wash-in of 1 nmol/L F-FKBP12.6. Higher [F-FKBP12.6] greatly enhances the rate constant of wash-in, k in (eg, Figure 6B ) and is stable during 30 minutes. Similar to FRAP analysis, k in depends on both k on and k off (k in ϭk on [F-FKBP]ϩk off ). After steady-state, the superfusate contained 33 nmol/L WT-FKBP12.6 (but lacked F-FKBP to prevent rebinding and have wash-out rate approximate k off ). The wash-out rate constant was no different in the absence of WT-FKBP12.6, suggesting that rebinding was negligible. The inferred k on and k off here are more variable, but agree with the FRAP measurements for both FKBP12 and 12.6 ( Figure 6C through 6E and Online Table I ). Wash-in/out experiments were also done after cAMP/OA exposure, and again binding characteristics were not altered for FKBP12 or 12.6 ( Figure 6C through 6E and Online Figure V) .
Binding Kinetics Measured by Continuous F-FKBP Wash-in/-out
Remarkably, rapamycin did not alter F-FKBP12.6 (or F-FKBP12) wash-out kinetics ( Figure 6C through 6E and Online Figure V) . We infer that the rapamycin binding site on FKBP is only accessible when FKBP is not RyR2-bound. Thus, rapamycin acts by complexing with free FKBP12.6 to prevent its binding to RyR2, without interfering with RyR2associated FKBP12.6.
Endogenous FKBP12.6/12 Levels in Intact Rat Myocytes
Given the extremely slow k off of FKBP12.6 from RyR2 (Ͼ30 minutes; Figures 5 and 6) , we expect some endogenous FKBP12.6 to be retained after myocyte permeabilization, which could complicate our interpretation. So, it was surprising that the measured B max (Figure 4 ) matched the RyR2 monomer concentration in rat myocytes, 26 and that there was no discernable slow wash-in phase at high [F-FKBP12.6] (eg, Figures 3A and 6B) as endogenous FKBP12.6 gradually dissociated. This raises the possibility that endogenous [FKBP12.6] in myocytes is low compared to RyR2, giving a low fractional occupancy of RyR2 with FKBP12.6 in myocytes. That would also explain why RyR2 activity is virtually unaffected in FKBP12.6-KO mice. 13 We measured amounts of endogenous FKBP12.6 and FKBP12 using three strategies. First, we compared total available F-FKBP12.6 binding sites in WT versus FKBP12.6-KO mouse myocytes (as in Figure 6B with 100 nmol/L F-FKBP12.6). If WT mice exhibit substoichiometric occupancy of RyR2s by endogenous FKBP12.6, the apparent B max would be lower in WT versus FKBP12.6-KO mice. We took advantage of the very slow k off and fast k on of FKBP12.6, washing in saturating [F-FKBP12.6] (100 nmol/L) to rapidly reach steady-state binding (within 10 minutes), and minimize endogenous FKBP12.6 dissociation. F-FKBP12.6 had the same binding affinity for RyR2 in WT and FKBP12.6-KO myocytes, but B max was 20% smaller in WT versus KO mice (not significant; Figure 7A ). Thus, at most Ϸ20% of RyR2 sites are occupied with native FKBP12.6 in WT myocytes (consistent with 100 to 200 nmol/L cellular [FKBP12.6], assuming 0.5 to 1 mol/L cytosol of RyR2 monomer). 26 Second, we intentionally predepleted myocytes of native FKBP12.6 by preincubating intact myocytes with rapamycin (2 mol/L) both before (1 to 2 hour, 37°C) and during permeabilization (followed by wash-out of rapamycin). In those studies, the apparent B max from F-FKBP12.6 experiments was only slightly increased by predepletion (10% to 15%, not shown).
Third, we directly measured endogenous FKBP12.6/12 in intact rat ventricular myocytes by western blot and FKBP concentration standards to establish a calibration curve (Fig- . Endogenous FKBP12.6/12 quantification. A, Apparent K d and B max measurement in myocytes from WT and FKBP12.6-KO mice (nϭ3 mice, 50 to 100 myocytes/mouse). B, Immunoblot quantification of endogenous total FKBP12/12.6 from intact rat myocytes (nϭ4 rats). C, RyR2 phosphorylation detected by P-S2808 -specific antibody, and normalized to RyR protein, for myocytes treated as in Figure 3A (before and 5 minutes after saponin exposure and 30 minutes after cAMP/OA and FKBP12.6 exposure). ure 7B). The first two lanes show a mixture of FKBP12/12.6 detected with antibodies that are FKBP12.6-specific (Laurent Vinet, INSERM U698, F-75018, Paris, France) and to a common epitope in both FKBPs. FKBP12 and 12.6 migrate slightly differently allowing simultaneous detection. The average total FKBP12 was 6Ϯ1.5 fmol/g cell lysate, which implies 1.05 mol/L cytosol of FKBP12 (based on 168 mg myocyte protein/mL cytosol 30 ). We could not detect FKBP12.6 with either antibody in myocyte homogenates. Therefore the total amount of FKBP12.6 must be lower than the lowest detectable FKBP12.6 standard, ie, [FKBP12.6] Յ100 to 150 nmol/L cytosol. This agrees with the independent analysis above (at 100 nmol/L, only 10% to 15% of RyR2 monomers in the myocyte can possibly have FKBP12.6 bound), and the relative predominance of FKBP12 versus 12.6 observed by many investigators. Thus, FKBP12:FKBP12.6 is Ͼ10:1 in cardiac myocytes, and [FKBP12] is roughly stoichiometric with RyR2 monomer concentrations.
Discussion
Using fluorescent FKBP and confocal microscopy of cardiac myocytes, we: (1) made the first in situ characterization of FKBP-RyR2 binding properties (on/off rates and K d ); (2) defined functional consequences of FKBP-RyR2 binding; (3) obtained further evidence that PKA-driven phosphorylation does not affect FKBP-RyR2 binding in the permeabilized myocyte setting; (4) estimated the amount of endogenous FKBP12.6 in mouse and rat myocytes; and (5) clarified the mechanism of rapamycin interference with FKBP/RyR binding.
FKBP12.6/12 Binds Specifically to RyR2
We used several approaches to ascertain that RyR2 is the predominant myocyte FKBP target. First, the F-FKBP12/12.6 striation patterns overlap Di-8-ANEPPS at T-tubules, where RyR2 is known to localize. Second, Ca sparks originated from F-FKBP labeled sites. Third, preincubation of myocytes with unlabeled FKBP12.6 completely abolished F-FKBP12 striations. Fourth, the FKBP B max measured equaled the concentration of myocyte RyR2 monomers. Fifth, we found strong and distinct FRET between F-FKBP12/12.6 donors and acceptor-labeled domains of calmodulin (F-CaM) in permeabilized myocytes, 31 which was similar to the FRET reported in skeletal muscle SR and purified RyR1. 24 Thus, in permeabilized cardiac myocytes, FKBP12.6 binds primarily to RyR2.
FKBP12.6/12 Binding Properties and Their Functions in Heart
A goal here was to measure FKBP-RyR2 interaction kinetics in situ in cardiac myocytes, because previous work used SR vesicles or cell lysates. [2] [3] [4] Three independent methods demonstrated that FKBP12.6 binds RyR2 with very high affinity (Ϸ1 nmol/L) and slow k off , giving average dwell time of FKBP12.6 on RyR2 of Ϸ20 minutes, thus unlikely to modulate beat-to-beat. This, and the substoichiometric FKBP12.6:RyR2 and lack of FKBP12 effect on CaSpF, explains why FKBP12.6 overexpression can decrease resting Ca leak and consequently increases SR Ca content and Ca transients. 11, 32 Indeed, FKBP12.6 here inhibited CaSpF and amplitude, while increasing SR Ca load (although the effects were modest).
Rapamycin did not accelerate FKBP12.6 dissociation from RyR2, but instead, prevented rebinding of FKBP12.6 to RyR2. Thus, it is the slow off-rate of FKBP12.6 that determines the velocity of rapamycin effects on RyR2 activity. This clarifies various previous results where rapamycin produced either unaltered RyR2 activity (or heart function) or only small changes in spark duration or width, etc. 7 However, lengthy rapamycin treatment indeed reverses FKBP12.6 effects in overexpression models, 11, 32 and in biochemical experiments. 14, 21 FKBP12 has a similar on-rate as FKBP12.6, but much faster off-rate and thus lower affinity. We could not detect effects of FKBP12 on RyR2 on CaSpF. This agrees with reports showing that coexpressing FKBP12.6 but not FKBP12 decreased Ca release triggered by an RyR2 activator (4-chloro-m-cresol) in CHO cells expressing hRyR2. 16, 18 However, FKBP12-deficient mice have normal skeletal muscles but severe dilated cardiomyopathy. 33 Overexpression of FKBP12 in rabbit cardiomyocytes caused reduced CaSpF, and increased spark amplitude and duration, and Ca transients. 17 Although these imply FKBP12 regulation of RyR2, a 48-hour rapamycin incubation was required to reverse the effects, whereas FKBP12 should dissociate from RyR2 within 5 minutes (Figure 2A ). Thus indirect pathways cannot be excluded. 34
FKBP12.6/12 Concentration and Its Physiological Role in Heart
We estimate endogenous myocyte FKBP12.6 and FKBP12 at 100 nmol/L and 1 mol/L, respectively ( Figure 6 ). Low total [FKBP12.6] and high affinity for RyR2, indicate that Ͼ99% of myocyte FKBP12.6 is bound to RyR2, with subnanomolar free FKBP12.6. Our data also suggest that Յ20% of FKBP binding sites are occupied by native FKBP12.6 (Figure 7) , so Ͼ80% of RyR2 are available to bind FKBP12. Furthermore, the fast k off of FKBP12 means that permeabilizing myocytes allows endogenous FKBP12 to diffuse out ( Ϸ25 s).
More than 80% of endogenous RyR2 are FKBP12.6-free. If FKBP12.6 binding were critical for normal RyR2 function (preventing SR Ca depletion and arrhythmias), then both normal myocytes and FKBP12.6-KO mice would be in an extremely precarious situation. Notably, female FKBP12.6-KO mice have no cardiac dysfunction, myocytes exhibit enhanced Ca transients and larger Ca sparks 35 and bilayer experiments showed unaltered RyR2 activity. 14 Although one group found exercise-induced arrhythmias and RyR2 channel hyperactivation in FKBP12.6-KO mice (only after exercise), 9 another found no difference in stress-induced arrhythmias. 14 This controversy is unresolved, but whether there is zero FKBP12.6 or 10% to 20% saturation of RyR2 (WT myocytes), SR Ca uptake and release can function relatively normally. Thus, although FKBP12.6 can inhibit diastolic RyR2 activity, the effect is moderate, and in vivo most RyR2 must achieve physiological stability somehow other than FKBP12.6 binding.
These permeabilized myocyte studies are most relevant to diastolic SR Ca release, which can be arrhythmogenic, and SR Ca release during Ca current triggered release may be differently regulated. For example, PKA can accelerate the rate of SR Ca release and inactivation in myocytes when Ca current and SR Ca load are held constant. 36 
Relevance to HF: PKA-Driven Phosphorylation and FKBP12.6/12-RyR2 Binding
Defective RyR2 regulation is linked to cardiac arrhythmias and contractile dysfunction in HF, via diastolic SR Ca leak via RyR2. 9, 19, [37] [38] [39] Extensive publications by Marks and coworkers support the theory that, in HF, RyR2 hyperphosphorylation by PKA disrupts FKBP12.6-RyR2 binding, thereby enhancing SR Ca leak and unloading. 9, 19, 37, 40, 41, 42 Some data from others support components of this model, 39, 43 but key aspects have been challenged by work showing either that RyR2 hyperphosphorylation fail to occur in HF, that PKA-dependent RyR2 phosphorylation does not cause FKBP12.6 dissociation, RyR2 activation, or SR Ca leak, or that FKBP12.6 does not alter RyR2 gating. 20, 21, 40 Our results cannot resolve this controversy, but provide new quantitative information about FKBP binding in the normal myocyte environment, with directly parallel functional data. In particular, we did not find any effect of PKA-dependent RyR2 phosphorylation on FKBP12.6 binding (measured 3 different ways). On the other hand, we detected significant diastolic RyR2 inhibition by FKBP12.6 (but not FKBP12). Our finding of low fractional saturation of RyR2 with FKBP12.6 in myocytes also means that even if FKBP12.6 association is reduced in HF, it could only occur at a minority of RyR2 (which would make those RyR2s like the others, in that respect). Of course, other effects in HF (eg, redox modulation or calcium/calmodulin-dependent protein kinase [CaMK]IIdependent phosphorylation 39, 44, 45 ) may alter RyR2 responsiveness to FKBP or PKA-dependent phosphorylation.
